Related Experiment Videos
Human antibody reactivity against the lower matrix protein (pp65) produced by cytomegalovirus
M Ohlin1, B Plachter, V A Sundqvist
1Department of Immunotechnology, Lund University, Sweden.
Abstract:
The lower matrix protein (pp65) is a major product of many laboratory strains of cytomegalovirus (CMV). It is thus an integral part of many CMV serological assays based on native antigen. Recombinant fragments of pp65 have previously been investigated for their usefulness in more-defined assays. The latter antigens have, however, failed to develop a positive response with serum samples derived from a substantial number of infected individuals. Here we show that the human humoral immune response to CMV pp65 is highly diverse and recognizes at least seven distinct but in some cases partly overlapping epitopes. Most of these epitopes could not be mimicked by any of the investigated recombinant or synthetic antigens. Furthermore, when we investigated the ability of human CMV-seropositive serum samples to block the reactivity of pp65-specific antibodies recognizing five different epitopes within pp65, it was evident that several sera did not contain significant levels of antibodies against any of these or overlapping structures. It was thus concluded that the antibody response against CMV pp65 is weak in some CMV-infected individuals, making this antigen unsuitable for use alone in serological screening systems for CMV infection.
Insights
Cytomegalovirus (CMV) pp65 antigen recognition is diverse, with many epitopes not mimicked by current recombinant assays. This limits pp65
Area of Science:
- Virology
- Immunology
- Serology
Background:
- Cytomegalovirus (CMV) lower matrix protein (pp65) is a key antigen in serological assays.
- Previous recombinant pp65 fragments showed limited diagnostic utility.
Purpose of the Study:
- To investigate the diversity of human immune responses to CMV pp65.
- To evaluate the efficacy of current recombinant antigens in detecting CMV infection.
Main Methods:
- Analysis of human humoral immune response to CMV pp65.
- Testing of recombinant and synthetic pp65 antigens.
- Serum sample analysis for antibody reactivity and epitope recognition.
Main Results:
- Human immune response to pp65 is diverse, recognizing at least seven distinct epitopes.
- Most epitopes were not replicated by tested recombinant or synthetic antigens.
- Several CMV-seropositive sera lacked significant antibodies against key pp65 epitopes.
Conclusions:
- CMV pp65 antigen recognition is highly variable among infected individuals.
- Current recombinant pp65 antigens are insufficient for comprehensive CMV serological screening.
- The antibody response to pp65 can be weak, impacting diagnostic accuracy.